ReviewFrontiers in pharmacology2021
Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Adjuvant Treatment of Coronary Heart Disease in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.Journal of diabetes research · 2022Pooled it
- Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow.Frontiers in pharmacology · 2022Pooled it
- Efficacy and safety of Yingxin pill for stable angina pectoris with heart blood stasis obstruction syndrome: a randomized, single-blind, positive-controlled trial.Frontiers in pharmacology · 2026Trial
- Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.Chinese journal of integrative medicine · 2026Article
- Effects of Shexiang Baoxin pill combined with exercise rehabilitation training on long-term prognosis of CTO-PCI patients: study protocol for randomized controlled trial.Frontiers in medicine · 2025Article
- Coronary microcirculatory dysfunction after percutaneous coronary intervention: pathogenesis, diagnosis, and therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
- Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure.European journal of medical research · 2024Review
- Study on the Therapeutic Value of Shexiang Tongxin Dropping Pills in Patients with Stable Angina Pectoris of Coronary Heart Disease Complicated with Cognitive Impairment.Actas espanolas de psiquiatria · 2024Article
- Efficacy and safety of oral Chinese patent medicines in the treatment of coronary heart disease combined with hyperlipidemia: a systematic review and network meta-analysis of 78 trials.Chinese medicine · 2023Review
- Single-nucleus ribonucleic acid-sequencing and spatial transcriptomics reveal the cardioprotection of Shexiang Baoxin Pill (SBP) in mice with myocardial ischemia-reperfusion injury.Frontiers in pharmacology · 2023Article
- Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Protective effects of muscone on traumatic spinal cord injury in rats.Annals of translational medicine · 2022Article
- Article
- Traditional chinese medicine in coronary microvascular disease.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.